US FDA Approves Abiomed’s Impella For Cardiogenic Shock Ahead Of Schedule
This article was originally published in Clinica
Executive Summary
US FDA has approved earlier than anticipated Abiomed’s Impella 2.5, Impella CP, Impella 5.0 and Impella LD transcatheter ventricular assist devices to provide treatment of ongoing cardiogenic shock.
You may also be interested in...
FDA Lowers Barrier To Market Penetration For Abiomed's Impella With Expanded Indication
FDA has removed "depressed ejection fraction" from the approved indication for Abiomed's Impella 2.5 and Impella CP based on results from the cVAD registry. The registry data support expanding the FDA-approved indication for the heart pumps during elective and urgent high-risk percutaneous coronary interventions, as well as for patients with cardiomyopathy leading to cardiogenic shock.
Device Debuts: Spinal Innovation From NuVasive, Life Spine; Teleflex Targets EuroPCR For Arrow AC3 Optimus; Abiomed Pushes 3-G Impella
This edition of Device Debuts covers the innovative devices introduced into commercial markets since the mid-April, typically a busy time for product launches as it coincides with spring's big medical meetings. This includes a series of spine-surgery technologies showcased at the AANS meeting and devices that support blood circulation during interventions that were featured at EuroPCR and SCAI.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.